Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.

Both the resistance of tumor cells to cisplatin and dose-related toxicity remain two of the most important problems in the chemotherapy of clinical oral squamous cell carcinoma (OSCC). Researchers have been seeking a combinative treatment regimen to improve the effect of chemotherapy. As potent new anti-cancer drugs, histone deacetylase inhibitors (HDACI(S)) have been reported to be associated with chromatin modification and display synergistic activities with some traditional chemotherapeutic agents. In this study, we evaluated the potential combinative effect of low dose cisplatin and suberoylanilide hydroxamic acid (SAHA, one of the most potent HDACI(S)) in OSCC cell lines. Cell viability and apoptotic assay were examined. Compared with either cisplatin (4 microg/ml) or SAHA (2 microM) treated alone, co-administration of both drugs synergistically induces cytotoxicity and apoptosis in both Tca8113 and KB cell lines. Furthermore, diverse apoptosis-associated proteins, including p53, BID, cytochrome C and caspase-3 were involved in the induction of apoptosis. Our results suggest that concurrent treatment with SAHA enhances tumor cell sensitivity to subtoxic doses of cisplatin. This may be regarded as a novel strategy for treatment of OSCC.

[1]  M. Burian,et al.  Phase II Study with Docetaxel and Cisplatin in the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2002, Oncology.

[2]  X. Lin,et al.  Identification of genes that mediate sensitivity to cisplatin. , 2001, Molecular pharmacology.

[3]  C. Henderson,et al.  Role of WHO. , 1982, Experientia. Supplementum.

[4]  Seth M. Cohen,et al.  Cisplatin: from DNA damage to cancer chemotherapy. , 2001, Progress in nucleic acid research and molecular biology.

[5]  D. Vigushin,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002, Anti-cancer drugs.

[6]  S. Lippman,et al.  Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. , 2000, Seminars in oncology.

[7]  P. Wingo,et al.  Cancer statistics, 1995 , 1995, CA: a cancer journal for clinicians.

[8]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  N. Bleehen,et al.  Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. , 1996, British Journal of Cancer.

[10]  John Calvin Reed,et al.  Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines , 2004, Apoptosis.

[11]  D. Durrant,et al.  The cardiolipin-binding domain of Bid affects mitochondrial respiration and enhances cytochrome c release , 2004, Apoptosis.

[12]  P. Munster,et al.  Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ , 2005, Clinical Cancer Research.

[13]  D. Housman,et al.  p53 status and the efficacy of cancer therapy in vivo. , 1994, Science.

[14]  J. Robert.  Resistance to cytotoxic agents. , 2001, Current opinion in pharmacology.

[15]  F. Caponigro,et al.  Cisplatin, Raltitrexed, Levofolinic Acid and 5-Fluorouracil in Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study , 2002, Oncology.

[16]  G. Otterson,et al.  DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. , 2001, Cancer research.

[17]  S. Echigo,et al.  Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. , 2006, International journal of oncology.

[18]  Paul Dent,et al.  The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. , 2003, Blood.

[19]  Young Mi Whang,et al.  Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor β expression in head and neck squamous carcinoma (HNSCC) cells , 2005, Cancer Chemotherapy and Pharmacology.

[20]  L. Nielsen,et al.  Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer , 1999, Cancer Chemotherapy and Pharmacology.

[21]  Fan Zhang,et al.  Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance , 2002, Oncogene.

[22]  S. Lippard,et al.  Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin , 1995, Nature.

[23]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[24]  D. Fisher.  Apoptosis in cancer therapy: Crossing the threshold , 1994, Cell.

[25]  Y. Pommier,et al.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.

[26]  Vigushin Dm,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002 .

[27]  Joanna K. Sax,et al.  BID regulation by p53 contributes to chemosensitivity , 2002, Nature Cell Biology.

[28]  G. Clayman,et al.  Report of the Tenth International Symposium of the Foundation for Promotion of Cancer Research: Basic and Clinical Research in Head and Neck cancer. , 1997, Japanese Journal of Clinical Oncology.

[29]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Marks,et al.  Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid , 2005, Nature Clinical Practice Oncology.

[31]  M. Blagosklonny.  How Cancer Could be Cured by 2015 , 2005, Cell cycle.

[32]  H. Hess-Stumpp.  Histone deacetylase inhibitors and cancer: from cell biology to the clinic. , 2005, European journal of cell biology.

[33]  H. Humes.  Insights into Ototoxicity , 1999 .

[34]  H. Humes.  Insights into ototoxicity. Analogies to nephrotoxicity. , 1999, Annals of the New York Academy of Sciences.

[35]  D. Vaux,et al.  Alterations in the apoptotic machinery and their potential role in anticancer drug resistance , 2003, Oncogene.

[36]  C. Giandomenico,et al.  Current Status of Platinum-Based Antitumor Drugs , 1999 .

[37]  Jin H. Song,et al.  Role of death receptor and mitochondrial pathways in conventional chemotherapy drug induction of apoptosis. , 2006, Cellular signalling.

[38]  F. Zheng,et al.  Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[39]  F. Zindy,et al.  Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter , 2004, Oncogene.

[40]  W. Denny,et al.  DNA and the chromosome – varied targets for chemotherapy , 2004, Cell & chromosome.

[41]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[42]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[43]  D. Conrad,et al.  Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways , 2003, Cancer biology & therapy.